[Federal Register Volume 59, Number 131 (Monday, July 11, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-16696]
[[Page Unknown]]
[Federal Register: July 11, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to Steven M.
Ferguson, Technology Licensing Specialist, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext.
266; fax 301/402-0220). A signed Confidential Disclosure Agreement will
be required to receive copies of the patent applications. Issued
patents may be obtained from the Commissioner of Patents, U.S. Patent
and Trademark Office, Washington, DC 20231.
Anti-Retroviral Compounds
Tam, S., Weigle, M., Broder, S., Mitsuya, H. (NCI)
Serial No. 07/064,631
Patent Reissued 14 Apr 92
U.S. Patent No. Re 33,887
Dimeric dideoxynucleosides formed from two different 2',3'-
dideoxynucleosides joined by a linking group are useful for treatment
of HIV-infection and other retroviral infections. The linked
dideoxynucleosides specifically inhibit HIV replication in vitro with
less toxicity in human cells. Methods for the synthesis of these
compounds are provided.
Method of Inhibiting Viral Replication Using IL-10
Yarchoan, R., Saville, W., Tosato, G., Taga, K. (NCI)
Filed 24 May 93
Serial No. 08/066,785
The use of recombinant human interleukin 10 (rhIL-10) has been
discovered to be a new potential means of treating HIV infection. In
vitro studies with rhIL-10 have shown it to be an inhibitor of HIV
infection in human monocytes and macrophages as well as having activity
against HIV in certain T-cell and monocyte cell lines. This activity
against HIV occurs both at the time of infection and when added to
previously infected cell cultures.
These effects occur at IL-10 concentrations that are lower than
those which inhibit other immune functions. In addition, the use of IL-
10 to interfere with HIV replication is expected to result in the
amelioration of Kaposi's sarcoma.
Novel Nonpeptidic Retroviral Protease Inhibitors
Randad, R., Pan, W., Burt, S., Erickson, J. (NCI)
Filed 8 Aug 93
Serial No. 08/106,686
Novel nonpeptidic compounds designed to be inhibitors of the HIV
protease enzyme have been discovered. These compounds thus have
potential as possible pharmaceutical compositions for the inhibition
HIV replication and the treatment of AIDS. Based upon SS isomers of
substituted dibenzyl-5-hydroxyl-2-primidones, these compounds are
expected to not have the problems associated with current peptide-based
protease inhibitors such as poor oral absorption, poor stability, and
rapid metabolism and elimination.
Use of Peptomers Derived From HIV-1 and HIV-2 as Vaccine Candidates
Robey, F., Harris-Kelson, T., Robert-Guroff, M. (NIDR)
Filed 19 Jan 94
Serial No. 08/184,330
Novel conformationally constrained peptide polymer HIV vaccine
candidates have been uncovered that generate a strong humoral immune
response not seen against monomeric peptides. Termed ``peptomers'',
these candidates are composed of specifically cross-linked synthetic
peptide sequences from the highly conserved CD4 binding domains of the
gp120 regions of HIV-1 and HIV-2. Although peptides from these regions
of gp120 do not possess any conformation in solution, the polymerized
forms were found to have conformations that resemble the theoretical
conformations that might be found in these regions of the native gp120
from HIV-1 and HIV-2. Certain peptomers from HIV-1 and HIV-2 bind CD4,
the cell receptor for HIV-1 and HIV-2, and induce antibody responses in
rabbits and rhesus monkeys that block in vitro HIV-1 infection.
Dated: June 25, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-16696 Filed 7-8-94; 8:45 am]
BILLING CODE 4140-01-P
